Jay S. Skyler - 16 Dec 2025 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Reporting relationship: Director
Issuer ticker: SABS
Reported as of: 16 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Dec 2025, 16:55:03 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jay S. Skyler

Key filing fact

Jay S. Skyler filed Form 4 for SAB Biotherapeutics, Inc. (SABS) on 18 Dec 2025.

Key facts

This page summarizes Jay S. Skyler's Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Dec 2025, 16:55.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001236386 Primary reporting owner

SKYLER JAY S

Relationship: Director
Address: 777 W 41ST STREET, SUITE 401, SUITE 401, MIAMI BEACH
Signature: /s/ Jay S. Skyler
Signature date: 18 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SABS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 16 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $3.99
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

Footnote F2

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.